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Corticosteroid Injection in Diabetic Patients
with Trigger Finger
A Prospective, Randomized, Controlled Double-Blinded Study
By Keith M. Baumgarten, MD, David Gerlach, MD, and Martin I. Boyer, MD, FRCS
Investigation performed at Washington University School of Medicine, St. Louis, Missouri
Background: It is generally accepted that the initial treatment for trigger ﬁnger is injection of corticosteroid into
the ﬂexor tendon sheath. In this study, the efﬁcacy of corticosteroid injections for the treatment of trigger ﬁnger in
patients with diabetes mellitus was evaluated in a prospective, randomized, controlled, double-blinded fashion and
the efﬁcacy in nondiabetic patients was evaluated in a prospective, unblinded fashion.
Methods: Thirty diabetic patients (thirty-ﬁve digits) and twenty-nine nondiabetic patients (twenty-nine digits)
were enrolled. The nondiabetic patients were given corticosteroid injections in an unblinded manner. The cohort
with diabetes was randomized into a corticosteroid group (twenty digits) or a placebo group (ﬁfteen digits). Both of
these groups were double-blinded. Additional injections, surgical intervention, and recurrent symptoms of trigger
ﬁnger were recorded. Treatment success was deﬁned as complete or nearly complete resolution of trigger ﬁnger
symptoms such that surgical intervention was not required.
Results: After one or two injections, twenty-ﬁve of the twenty-nine digits in the nondiabetic group had a success-
ful outcome compared with twelve of the nineteen in the diabetic corticosteroid group (p = 0.03) and eight of the
ﬁfteen in the diabetic placebo group (p = 0.006). With the numbers studied, no signiﬁcant difference was found
between the diabetic groups. Surgery was performed in three of the twenty-nine digits in the nondiabetic group
compared with seven of the nineteen in the diabetic corticosteroid group and six of the ﬁfteen in the diabetic
placebo group. There was a signiﬁcant difference in the prevalence of surgery between the nondiabetic group and
both the diabetic corticosteroid group and the diabetic placebo group (p = 0.035 and p = 0.020, respectively). With
the numbers studied, no difference was found between the diabetic groups with regard to the persistence of
symptoms. Nephropathy and neuropathy were signiﬁcantly associated with the need for surgery (p = 0.008 and p =
0.03, respectively).
Conclusions: Corticosteroid injections were signiﬁcantly more effective in the digits of nondiabetic patients than
in those of diabetic patients. In patients with diabetes, corticosteroid injections did not decrease the surgery rate
or improve symptom relief compared with the placebo. The use of corticosteroid injections for the treatment of
trigger ﬁnger may be less effective in patients with systemic manifestations of diabetes mellitus.
Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.
T
he prevalence of trigger ﬁnger in the general popula-
tion has been reported to be 3%1. It is generally accepted
that the initial treatment of choice for trigger ﬁnger is
an injection of corticosteroid into the affected ﬂexor tendon
sheath2-6. This treatment has been shown to decrease local
pain, tenderness, and locking as well as to improve grip and
function. Since the treatment was ﬁrst described by Howard
et al. in 19537, consistent success rates of up to 80% have been
reported4,5,8. These studies have also demonstrated that a sec-
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recent prospective study demonstrated that 64% of patients
treated with a single corticosteroid injection had relief of
symptoms compared with 20% of patients treated with a
placebo injection6. This study did not include patients with
diabetes mellitus; therefore, these ﬁndings do not demonstrate
whether the clinical course of such patients is different from
that of nondiabetic patients.
Several studies have demonstrated that the prevalence of
trigger ﬁnger in patients with diabetes is signiﬁcantly higher
than that in the general population. In one comparative pro-
spective study, 23% of patients with insulin-dependent diabe-
tes mellitus and 16% of non-insulin-dependent diabetics were
diagnosed with a trigger ﬁnger compared with 2% of normo-
glycemic control patients (p < 0.01)9. In another case-control
study, the prevalence of trigger ﬁnger in diabetic patients was
17%, whereas only 3% of nondiabetic patients had a trigger
ﬁnger (p < 0.05)1.
Observational studies have suggested that corticosteroid
injection for the treatment of trigger ﬁnger is not as effective
in diabetic patients as it is in the general population10-12. One
retrospective review showed that diabetic patients responded
less favorably to corticosteroid injection, with only 50% hav-
ing relief after one, two, or three injections10. A second study
demonstrated a clinical success rate of only 66% at one year
after multiple injections11. A third retrospective case-control
study showed that corticosteroid injection for trigger ﬁnger
was signiﬁcantly more effective in nondiabetic patients than in
diabetic patients (p < 0.0001), with rates of symptom resolu-
tion of 76% and 49%, respectively (p < 0.0001)12. These studies,
supported by empiric or retrospective data, cause one to ques-
tion the use of corticosteroid injections for the treatment of
trigger ﬁnger in diabetic patients.
The purpose of this double-blinded, randomized,
placebo-controlled, prospective study was to evaluate whether
(1) corticosteroid injection into the ﬂexor tendon sheath is as
effective in alleviating the symptoms of trigger ﬁnger in pa-
tients with diabetes mellitus as it is in nondiabetic patients, (2)
corticosteroid injection into the ﬂexor tendon sheath is more
effective than placebo injection for alleviating the symptoms
of trigger ﬁnger in diabetic patients, and (3) the degree of
glycemic control (as determined by measurement of serum
hemoglobin A1c level at the time of the initial injection) affects
the relief of symptoms of trigger ﬁnger with corticosteroid in-
jection in diabetic patients. The two null hypotheses of this
study were (1) a diagnosis of diabetes mellitus does not change
the effectiveness of corticosteroid injection for the treatment
of trigger ﬁnger, and (2) corticosteroid injection(s) into the
ﬂexor tendon sheath have no signiﬁcant effect on the resolution
of trigger ﬁnger symptoms in patients with diabetes mellitus.
Materials and Methods
Inclusion and Exclusion Criteria
The study subjects were selected from a consecutive groupof patients seen at the ofﬁces of four fellowship-trained
hand surgeons at one institution from March 2003 to July



































































































































































and had subjective symptoms of pain, catching, or triggering
along the A1 pulley, consistent with sterile ﬂexor tenosynovitis,
were eligible. These symptoms were conﬁrmed with objective
ﬁndings such as tenderness over the A1 pulley, a palpable
nodule at the A1 pulley or between the A1 and A2 pulleys, pain
along the ﬂexor tendon with resisted ﬂexion or with passive
stretch in extension, and reproducible locking, triggering, or
catching. Both patients with and those without diabetes mel-
litus were eligible for inclusion in this study. To be included
in the diabetes cohort, the patient had to have a diagnosis of
either insulin-dependent or non-insulin-dependent diabetes
and be under the care of an internist or endocrinologist prior to
his or her initial presentation to us for inclusion.
Exclusion criteria for this study were (1) previous treat-
ment of the trigger ﬁnger with surgical release of the A1 pulley
or with corticosteroid injection; (2) an inﬂammatory or poten-
tially pathologic etiology, such as rheumatoid arthritis, of the
trigger ﬁnger(s); the patient’s unwillingness to consider oper-
ative management of the trigger ﬁnger (as surgery was one of
the end points of this study); and (4) an inability to tolerate
injections into the ﬂexor sheath or venipuncture for determi-
nation of hemoglobin A1c levels or previous adverse reactions
to corticosteroids or local anesthetics.
All patients whomet the criteria were offered enrollment,
and ﬁfty-nine (twenty-nine nondiabetic and thirty diabetic)
patients agreed to participate. There were twenty-one men and
thirty-eight women. After the study rationale was explained
by the treating hand surgeon and an informed consent form
approved by the human studies committee at our institu-
tion was signed, a standardized initial study interview and
examination were performed. Data that were recorded for all
patients included age, handedness, occupation, presence of
diabetes, type of diabetes, duration of diabetes, amount and
type of insulin used per day, other systemic diabetic manifesta-
tions (retinopathy, neuropathy, or nephropathy), carpal tun-
nel syndrome, Dupuytren disease, affected hand(s), affected
digit(s), and symptoms. All patients, including those without
a diagnosis of diabetes, had blood drawn to determine the
hemoglobin A1c level at the initiation of the study.
Randomization
Diabetic patients were randomized into either the corticoste-
roid or the placebo group by a blinded, prestudy drawing
of cards labeled as either ‘‘corticosteroid’’ or ‘‘placebo.’’ All
injections were prepared by the study coordinator and ad-
ministered, by a fellowship-trained hand surgeon, in opaque
syringes that hid the appearance of the injectate from both the
surgeon and the patient. Both investigators (K.M.B. and D.G.)
responsible for data analysis were blinded to the treatment
method as well. All patients in the nondiabetic control arm of
the study were treated with corticosteroid injection in a non-
blinded fashion.
Injections
Patients assigned to the corticosteroid arm were injected with
a mixture of 1.0 mL (6 mg) of betamethasone sodium
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phosphate/acetate solution (Celestone Soluspan) and 0.5 mL
(5 mg) of 1% lidocaine. Placebo injections consisted of 0.5 mL
(5 mg) of 1% lidocaine and 1 mL of sterile saline solution.
Patients with partial relief or recurrence of symptoms
were treated with a second and/or third injection with at least
three months between injections. These additional injections
all consisted of corticosteroid, even in the placebo group. We
thought that it was unethical to continue with placebo treat-
ment if patients had major, persistent symptoms that required
a second injection. However, the surgeon remained blinded to
the contents of the original injection.
Follow-up
Patients were interviewed and reexamined at six weeks, three
months, and one year, or at more frequent intervals if they
were having increased or persistent symptoms. Follow-up in-
cluded evaluation of the subjective symptoms and physical
ﬁndings consistent with trigger ﬁnger (objective triggering,
tenderness at the A1 pulley, and presence of a painful nodule)
as well as any complications related to the treatment.
Failure of Treatment
If symptoms recurred following a third injection of corti-
costeroid or if the patient obtained no relief from any of the
three injections, the patient was offered surgical release of the
A1 pulley. Treatment failure was deﬁned as persistence of local
pain, tenderness, and locking of the ﬂexor tendon that the
patient believed warranted surgical intervention. Treatment
success was deﬁned as either complete or nearly complete
resolution of local pain, tenderness, and locking of the ﬂexor
tendon that obviated the need for surgical release or another
injection into the A1 pulley. The decision to pursue surgery
instead of continuing the injections was subjectively deter-
mined by the patient and the hand surgeon on the basis of the
degree and duration of symptom relief and the recurrence of
symptoms.
Power Analysis
A prestudy statistical analysis was performed to determine the
number of digits required in each trial group to achieve an
alpha value of 0.05 (degree of signiﬁcance) and a power of 0.8
(a beta value of 0.2). If the proportion of diabetic cases treated
with corticosteroids that eventually undergo surgery is ap-
proximately 0.5, as reported by Griggs et al.10, and the propor-
tion of untreated cases that eventually undergo surgery is 1.0, as
reported by Murphy et al.6, a minimum sample size of ap-
proximately seventeen digits in each group (diabetic cortico-
steroid, diabetic placebo, and nondiabetic), for a total sample
size of ﬁfty-one digits, is required to achieve the stated power
per group. These cohort sizes are based on an assumed dif-
ference in population means of 0.5, a within-group standard
deviation of 0.5, and approximately equal numbers of study
participants in each group. The study was powered sufﬁciently
to demonstrate (1) at least a 50% difference between the results
of corticosteroid injection and those of placebo injection



































































































































































diabetic digits and nondiabetic digits with regard to symptom
resolution resulting from corticosteroid injection.
Data Analysis
An intention-to-treat analysis was performed. According to
the principles of this analysis, digits in the placebo group that
received additional injections that included corticosteroid
were analyzed within the placebo group. Analysis of variance
was used to compare continuous data, and the chi-square test
was used to compare discrete data. Survival analysis was per-
formed with use of proportional hazards regression tech-




Fifty-nine patients were initially enrolled in the study.Twenty-nine patients (twenty-nine digits) did not have
diabetes mellitus and thus served as the control subjects. Thirty
patients had a prior diagnosis of diabetes mellitus; fourteen of
them (ﬁfteen digits) were randomized into the placebo group
and seventeen (twenty digits), into the corticosteroid group.
One patient with involvement of two digits was random-
ized into both groups, with one digit assigned to the diabetic
placebo group and one assigned to the diabetic corticosteroid
group.
Three digits crossed over from the diabetic placebo
group to the diabetic corticosteroid group. One received one
corticosteroid injection, one received two corticosteroid in-
jections, and one received one corticosteroid injection and then
underwent a subsequent surgical release of the A1 pulley. These
three digits were kept in the diabetic placebo group for the
intention-to-treat data analysis13. One patient (one digit) in the
diabetic corticosteroid group was lost to follow-up after six
weeks; this patient was not included in the study analysis.
There were no signiﬁcant differences between the non-
diabetic and diabetic patients with regard to age, gender,
handedness, affected hand, or affected digits (p > 0.05). These
two groups did differ signiﬁcantly with regard to the mean
hemoglobin A1c level (0.059 compared with 0.073; p = 0.0001)
and the prevalence of nephropathy, retinopathy, neuropathy,
and other pathologic conditions involving the hand (such as
carpal tunnel syndrome, Dupuytren disease, and joint con-
tractures) (p < 0.05). There were no signiﬁcant differences be-
tween the diabetic placebo and diabetic corticosteroid groups
with regard to age, gender, handedness, affected hand, affected
digits, or hemoglobin A1c level or the prevalence of insulin-
dependent diabetes, other hand diseases, neuropathy, ne-
phropathy, or retinopathy (Table I).
A ﬁnal follow-up evaluation was performed for ﬁfty-
eight patients between thirteen and forty-one months. The
mean duration of follow-up (and standard deviation) was
28 ± 7 months for the nondiabetic group, 23 ± 9 months for
the diabetic corticosteroid group, and 26 ± 10 months for
the diabetic placebo group (p > 0.05). Fifty-eight (98%) of the
original ﬁfty-nine returned for ﬁnal follow-up.
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Success of Injection Treatment
Twenty-two (76%) of the twenty-nine digits in the nondiabetic
group responded to a single corticosteroid injection. Six digits
required a second injection. After one or two injections, twenty-
ﬁve (86%) of the twenty-nine digits had relief of symptoms,
obviating the need for surgical intervention. Eleven of the
nineteen digits in the diabetic corticosteroid group responded
to a single corticosteroid injection. One digit required a second
injection. After one or two injections, twelve of the nineteen
digits had relief of symptoms, obviating the need for surgical
intervention. Seven of the ﬁfteen digits in the diabetic placebo
group responded to a single placebo injection. Three patients
(three digits) requested unblinding after the initial placebo in-









































(Table II). After one or two injections, eight of the ﬁfteen digits
in the diabetic placebo group had relief of symptoms so that
they did not require surgical intervention. One patient (one
digit) in the diabetic placebo group received a second cortico-
steroid injection (three injections in total). After one, two, or
three injections, nine of the ﬁfteen digits in the diabetic placebo
group had relief of symptoms that obviated the need for sur-
gery (Fig. 1). The outcomes of the injections in the diabetic
corticosteroid group and the diabetic placebo group were sim-
ilar after both the ﬁrst (p = 0.52) and second injections (p =
0.56). There was no signiﬁcant difference in the results after the
ﬁrst injection between the nondiabetic group and either the
diabetic corticosteroid group (p = 0.30) or the diabetic placebo
group (p = 0.09). However, there were signiﬁcant differences
TABLE I Demographic Characteristics
Nondiabetic Group Diabetic Corticosteroid Group*† Diabetic Placebo Group†
No. of patients 29 16 14
No. of digits 29 19 15
Male‡ 9 6 7
Female‡ 20 10 7
Age§ 63.1 ± 11.7 62.9 ± 9.00 61.4 ± 9.12
Right-hand dominant# 27 19 15
Left-hand dominant# 2 0 0
Right hand affected# 21 10 7
Left hand affected# 8 9 8
Involved digit#
Thumb 7 4 2
Index ﬁnger 3 2 0
Long ﬁnger 8 8 6
Ring ﬁnger 10 4 7
Small ﬁnger 1 1 0
Hemoglobin A1c level§** 0.059 ± 0.0055 0.0726 ± 0.0044 0.0728 ± 0.0098
Other hand disease‡** 1 5 1
Carpal tunnel syndrome‡ 1 1 1
Dupuytren disease‡ 0 1 0
History of trigger ﬁnger in other digits‡ 0 2 0
Carpometacarpal osteoarthritis‡ 0 1 0
Non-insulin-dependent diabetes mellitus#** 0 12 10
Insulin-dependent diabetes mellitus# 0 7 5
Nephropathy#** 0 5 1
Retinopathy#** 0 2 0
Neuropathy#** 0 1 4
*One patient (one digit) was lost to follow-up and is not included. †One male patient (two digits) was randomized to both the diabetic
placebo group and the diabetic corticosteroid group. ‡The values are given as the number of patients. §The values are given as the mean
and standard deviation. #The values are given as the number of digits. **There was a signiﬁcant difference between the nondiabetic and
diabetic groups (p < 0.05). (There was no signiﬁcant difference in any characteristic between the diabetic corticosteroid group and the
diabetic placebo group.)
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in the results after the second injection between the nondiabetic
group and the diabetic corticosteroid group (p = 0.03) and the
diabetic placebo group (p = 0.006).
Surgerywas performed in three (10%) of the twenty-nine
digits in the nondiabetic group. (An additional patient [one
digit] requested surgery, but it had not been performed by the
time of ﬁnal follow-up.) Seven of the nineteen digits in the
diabetic corticosteroid group and six of the ﬁfteen digits in
the diabetic placebo group required surgical management (p =
0.035 and p = 0.020, respectively, for the comparisons with the
nondiabetic group). With the numbers studied, there was no
signiﬁcant difference in the frequency of surgery between the
two diabetic groups (p = 0.76).
Although many patients were considered to have had
successful treatment because they avoided surgery, not all of
them remained symptom-free at the time of ﬁnal follow-up.
Twenty of the twenty-six digits that were not treated with
surgery in the nondiabetic group were asymptomatic at the
time of ﬁnal follow-up compared with ten of the twelve digits
without surgery in the diabetic corticosteroid group (p = 0.65)
and seven of the nine digits without surgery in the diabetic
placebo group (p= 0.96).With the numbers available, there was
no signiﬁcant difference between the diabetic groups (p = 0.75).
In the intention-to-treat analysis, digits that had had









































































sidered to have been symptomatic. Twenty of the twenty-nine
digits in the nondiabetic group were asymptomatic at the
time of ﬁnal follow-up compared with ten of the nineteen
digits in the diabetic corticosteroid group (p = 0.25) and seven
Fig. 1
Success of nonoperative treatment. *There was a signiﬁcant difference between the nondiabetic group and the diabetic corti-
costeroid group (p = 0.03) and the diabetic placebo group (p = 0.006).









No. of patients 29 16 14



















THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 89-A d NUMBER 12 d DECEMBER 2007
CORTICOSTEROID IN JECT ION IN DIABET IC PATIENTS
WITH TRIGGER FINGER
of the ﬁfteen in the diabetic placebo group (p = 0.15). Again,
there was no signiﬁcant difference between the two diabetic
groups (p = 0.73).
At the time of ﬁnal follow-up, there was no difference be-
tween the two diabetic groups with regard to the persistence of
trigger ﬁnger symptoms, including subjective triggering (p =
0.72), objective triggering (p = 0.97), tenderness at the A1
pulley (p = 0.73), and a palpable, painful nodule (p = 0.97).
There was a signiﬁcant difference in the prevalence of a palp-
able, painful nodule between the nondiabetic group and the
diabetic corticosteroid group (p = 0.05). Subjective triggering
at the time of follow-up was more prevalent in the diabetic
placebo group than in the nondiabetic group (p=0.05) (Fig. 2).
Effect of Hemoglobin A1c
The serum hemoglobin A1c levels were determined at the time
of the patients’ initial ofﬁce visit and consent to enter into the
study. The mean hemoglobin A1c level was signiﬁcantly higher
in the diabetic groups (0.073) than in the nondiabetic group
(0.059) (normal = 0.040 to 0.060) (p = 0.0001). There was no
difference in the initial hemoglobin A1c levels between the two
diabetic groups (0.0726 compared with 0.0728; p = 0.95). The
only signiﬁcant interaction found between treatment success






































































Diabetic patients who responded to the placebo injection had
a lower mean hemoglobin A1c level than those who did not
respond to the initial injection and had a repeat injection (of
corticosteroid) or surgical intervention (0.068 compared with
0.076; p = 0.03).
Type of Diabetes and Diabetic Comorbidities
There was no signiﬁcant difference in the prevalence of surgery
(p = 0.55) or the response to the ﬁrst corticosteroid injection
(p = 0.51) between the patients with insulin-dependent
diabetes mellitus and those with non-insulin-dependent dia-
betesmellitus. Patients with diabetic neuropathy (p= 0.03) and
those with diabetic nephropathy (p = 0.008) were more likely
to undergo surgical intervention. Patients with diabetic ne-
phropathy were less likely to obtain symptom relief after the
ﬁrst injection and thus more likely to require either another
injection or surgical intervention (p = 0.04). However, no
signiﬁcant association was found between treatment out-
come and the presence of diabetic retinopathy. Although this
study demonstrated a signiﬁcant relationship between ne-
phropathy and neuropathy and decreased efﬁcacy of corti-
costeroid injection for the treatment of trigger ﬁnger, these
evaluations should be considered as suggestive because of the
small sample sizes.
Fig. 2
Persistence of trigger ﬁnger symptoms at the time of ﬁnal follow-up. *There was a signiﬁcant difference in the prevalence of a
palpable, painful nodule between the nondiabetic group and the diabetic corticosteroid group (p = 0.05). #Subjective triggering
at the time of follow-up was signiﬁcantly more prevalent in the diabetic placebo group than in the nondiabetic group (p = 0.05).
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Complications
There were no adverse events or complications associated
with the corticosteroid injections administered during this
study.
Discussion
We performed a prospective, randomized study to eval-uate the efﬁcacy of corticosteroid injection into the
ﬂexor tendon sheath for the treatment of trigger ﬁnger in both
diabetic and nondiabetic patients. Our ﬁndings conﬁrm that
corticosteroid injections are, in general, more effective in
nondiabetic patients than in diabetic patients, as has been
previously shown10-12. Speciﬁcally, nondiabetic patients were
signiﬁcantly more likely to avoid surgery than were diabetics
treated with corticosteroid injection and diabetics treated with
a placebo (surgical rates, three of twenty-nine compared with
seven of nineteen and six of ﬁfteen, respectively).
Prospective studies in the endocrinology literature have
implied that if diabetic patients manage their disease aggres-
sively and maintain nearly normal hemoglobin A1c levels, they
will exhibit fewer symptoms of retinopathy, neuropathy, and
nephropathy compared with diabetics who have higher hemo-
globin A1c levels
14. We had hypothesized that poorly controlled
diabetes mellitus might be a barrier to effective nonoperative
management of trigger ﬁnger, since diabetic patients experi-
ence trigger ﬁngermore often than does the general population
and high blood glucose levels portend more diabetic-related
complications and comorbidities. This study did demonstrate
that diabetic patients who responded to the placebo injection
had a signiﬁcantly lower mean hemoglobin A1c level than did
patients in the diabetic placebo group who had persistence
of symptoms requiring either surgery or a second injection
(crossover to corticosteroid treatment). This ﬁnding suggests
that patients with lower hemoglobin A1c levels are more likely
to have spontaneous resolution or amelioration of trigger
ﬁnger symptoms than are patients with poorly controlled dia-
betes mellitus. Further investigation may elucidate a threshold
of glycemic control in diabetic patients, above which nonop-
erative management of trigger ﬁnger may be signiﬁcantly less
effective.
We also hypothesized that patients with systemic man-
ifestations of diabetesmellitus would not respond as well to the
corticosteroid injection as would patients without nephrop-
athy, neuropathy, or retinopathy. Patients with diabetic ne-
phropathy had a higher prevalence of surgical intervention
(p = 0.008) and fewer successful responses to the ﬁrst cortico-
steroid injection (p = 0.04). In addition, patients with diabetic
neuropathy had a signiﬁcantly higher prevalence of surgical
intervention (p = 0.03). This suggests that the efﬁcacy of intra-
sheath corticosteroid injection may be decreased in patients
with systemic manifestations of diabetes. This may be due
to either a longer duration of the diabetes or less stringent
glycemic control.
Several potential limitations regarding the interpretation
of these data should be noted. Taras et al. reported that 17%



































































































































































with the injectate remaining subcutaneous15. Despite conﬁr-
mation of a ﬂuid wave along the ﬂexor tendon with the injec-
tion in all of our subjects, we did not obtain deﬁnitive proof
of accurate, intra-sheath injection. However, it has been shown
that resolution of trigger ﬁnger symptoms following subcuta-
neous injection is similar to that following injection into the
ﬂexor sheath15. Thus, while it is not impossible that inaccurate
injection played a role in the poor outcomes, it is unlikely. A
second potential limitation of the study lies in the statistical
analysis of the three patients who had involvement of multi-
ple digits. None of the nondiabetic patients had involvement
of multiple digits, but three patients with diabetes did. One
had involvement of four digits, all of which were treated with
a steroid injection; another had involvement of two digits,
both of which received a placebo injection; and a third had
involvement of two digits, one of which was treated with a
steroid injection and the other of which had a placebo injec-
tion. Because so few patients had involvement of multiple
digits, statistical analysis of this subgroup was not performed,
and these digits were by necessity analyzed as separate entities.
The results of this study should be interpreted in light of
the fact that three patients crossed over from the diabetic
placebo group to the corticosteroid treatment group. For
the purpose of data analysis, these three crossovers remained
in the diabetic placebo group according to the intention-to-
treat principles13, in order to protect the integrity of the ini-
tial randomization process. Two of these patients did not
require surgery after corticosteroid treatment, and one did. It
is important to note, however, that there was no signiﬁcant
difference between the diabetic corticosteroid group and the
diabetic placebo group with regard to the success of the in-
jection treatment before or after the crossovers occurred.
The lack of a proscribed objective criterion for surgical
intervention should be noted. Clinical decision-making re-
garding the transition from nonoperative treatment to oper-
ative treatment of trigger ﬁnger is by necessity subjective
and based on a discussion of risks and beneﬁts between the
patient and surgeon. Although the lack of a speciﬁc criterion
for surgery is a limitation of a scientiﬁc study, it reproduces
the clinical decision-making process in the treatment of trig-
ger ﬁnger. A ﬁnal limitation of the study is that patients for
whom one injection failed were not required to have a second
or third injection prior to considering surgical intervention.
Although additional injections were offered and may have
indeed obviated the need for surgery, we did not believe that it
was ethical to withhold surgery if the patient did not want to
undergo repeat injection.
Although no complications of corticosteroid injection
were found in this study, a previous study showed transient
hyperglycemia after corticosteroid injection into the ﬂexor
tendon sheath for the treatment of trigger ﬁnger16. Post-
injection blood glucose levels were not examined in our study.
In conclusion, given the absence of side effects in our
patients, we recommend corticosteroid injection as a sound,
low-risk primary treatment option for trigger ﬁnger in diabetic
patients irrespective of their glycemic control. However, it
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should be emphasized that the efﬁcacy of corticosteroid injec-
tion in diabetic patients is signiﬁcantly decreased compared
with that in nondiabetic patients. In addition, this study sug-
gests that patients with systemic diabetic manifestations may
have a poorer response to corticosteroid injections for the
treatment of trigger ﬁnger. n
NOTE: The authors thank Richard H. Gelberman, MD, Paul R. Manske, MD, and Charles A.
Goldfarb, MD, for their assistance with patient recruitment for this study, and Paul Thompson,
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